GBA Presents: House of Gummy-!

--Shift4 Payments initiated with a Buy at Mizuho » 16:07 FOUR

--Metals Acquisition initiated with a Buy at Canaccord » 16:41 MTAL

--HealthStream affirms FY23 revenue view of $277.5M-$283.0M, consensus $280.6M » 16:32 HSTM Affirms FY23 adjusted…

--HealthStream reports Q2 EPS 13c, consensus 9c » 16:31 HSTM


HealthStream, Inc. (HSTM)
NasdaqGS - NasdaqGS Real Time Price.
23.16-0.05(-0.22%)
At close: 04:00PM EDT
24.24+1.08(+4.66%)<-------------
After hours:05:49PM EDT
 
NOTABLE INSIDER PURCHASES: Significant insider purchases reported in the prior week from July 17 through July 21 include:


JOHN DEJORIA IS RICH:
  • Beneficial owner of HighPeak Energy (HPK) John DeJoria purchased 6,571,428 shares of company stock at $10.50 per share for a total transaction amount of $68,999,994


  • Beneficial owner of Joint Corp (JYNT) purchased 22,463 shares of company stock at $13.03 per share for a total transaction amount of $292,769


  • Beneficial Owner of Nuvectis Pharma (NVCT) Charles Mosseri purchased 9,149 shares of company stock at $14.84 per share for a total transaction amount of $135,771


  • Director of Theseus Pharmaceuticals (THRX) purchased 479,932 shares of company stock at $3.05 per share for a total transaction amount of $1,463,793
 
6b7cbc58c6f924921a284739fb2dfe7e

The Joint Corp.
SCOTTSDALE, Ariz., July 13, 2023 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care throughThe Joint Chiropractic®network, announced it will report its second quarter 2023 financial results on Thursday, August 10, 2023, after the market close. President and CEO Peter D. Holt and CFO Jake Singleton will hold a conference call at 5:00 p.m. EDT that day to discuss the results.
 
TOMORROW we look at BLUE--

The upside is huge, but beware of the risks
Bluebird Bio):Bluebird Bio is a gene-editing specialist currently sporting a market cap of $402 million, putting it squarely in small-cap territory. The biotech has encountered a series of clinical and regulatory setbacks over the past three years, leading to it losing nearly 90% of its value. Yet, there could be some hope for the company.

BLUE.png

Last year, Bluebird earned approval for two gene-editing therapies, Zynteglo and Skysona, that target transfusion-dependent beta-thalassemia (TDT) and active cerebral adrenoleukodystrophy, respectively. But the company's most important approval yet could be on the horizon. In April, Bluebird submitted an application to the U.S. Food and Drug Administration (FDA) for lovo-cel, a potential treatment for sickle cell disease (SCD).

Why could lovo-cel be a game changer for Bluebird? While Zynteglo and Skysona target a maximum of 1,540 patients in the U.S. between them, lovo-cel is looking at a much larger opportunity with about 20,000 eligible patients in the country. The FDA set a PDUFA action date(by when it should complete the review) of Dec. 20, 2023.


Still, as Bluebird's tiny market cap suggests, there remain plenty of risks with the stock. For instance, administering the company's gene-editing therapies is a long and complex process that can only be done in select qualified treatment centers. This factor considerably slows the pace at which Bluebird can treat patients and, by extension, generate money. Further, Bluebird could face some competition in the TDT and SCD markets, with Vertex Pharmaceuticals andCRISPR Therapeutics nearing the approval of exa-cel.

Lastly, Bluebird's Zynteglo and Skysona cost $2.8 million and $3 million, respectively. Their price tags could scare off some third-party payers.

All these crucial details make Bluebird's stock risky. However, the upside for the stock is enormous if the company can do three things. First, Bluebird must earn approval for lovo-cel without a hitch. Second it needs to continue the (so far) smooth launch of Zynteglo and Skysona. Third, the company must carve out a solid niche for itself in the TDT and SCD markets even with competition from larger biotechs.

There are huge potential rewards and huge potential risks with Bluebird. Invest accordingly.
 
stonedinvestor said:
Description

Flow Beverage Corp., a health and wellness focused beverage company, engages in production and distribution of original unflavored and collagen-infused alkaline spring water in the United States and Canada. The company's spring water available in natural flavours, such as blackberry+hibiscus, grapefruit+elderflower, strawberry+rose, watermelon+lime, cucumber+mint, lemon+ginger, watermelon, grapefruit, cucumber, peach+blueberry, blood orange, meyer lemon, pomegranate, elderberry, citrus, and cherry. It distributes its products under the Flow brand name through direct sales, broker/distributors, and direct-to-consumer/e-commerce channels. The company was formerly known as RG One Corp. and changed its name to Flow Beverage Corp. in April 2021. Flow Beverage Corp. was incorporated in 2014 and is headquartered in Aurora, Canada.

2 Springs 1 in Virginia and Carton selling /// 51,000 retail locations.

Water is special minerals more minerals than natural and more than any other premium water brand.

Calcium and Magnz... PH 8.1 <--------------- Electrolytes

Single use plastic to be displaced!!! ESG ratings highest rated beverage company in sustanablility!!!! Carbon neutral.

More...
Is it the next CELH?
 
You must log in or register to reply here.
Back
Top